Stockscreener 앱 받기
3.00
3.85%
-0.12
시간 외 거래:
3.03
0.03
+1.00%
Inmed Pharmaceuticals Inc 주식(INM)의 최신 뉴스
InMed Pharmaceuticals Struggles with Losses Amid Revenue Decline - MSN
InMed Pharmaceuticals Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update - Defense World
InMed Pharmaceuticals Board Reshuffle After Director Resignation - TipRanks
InMed Pharmaceuticals Reports Q2 2025 Financial Results - TipRanks
InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update - Yahoo Finance
InMed Pharmaceuticals Inc. (INM) reports earnings - Quartz
InMed Pharmaceuticals Inc. SEC 10-Q Report - TradingView
InMed Advances INM-089 for Dry AMD Treatment with New Intravitreal Formulation - TipRanks
Inmed selects IVT formulation of INM-089 for dry AMD - BioWorld Online
InMed advances AMD treatment with promising IVT drug formulation - MSN
Revolutionary Eye Drug INM-089 Achieves 10X Therapeutic Levels in Macular Degeneration Treatment - StockTitan
Inmed Pharmaceuticals Inc (INM-Q) QuotePress Release - The Globe and Mail
InMed Pharmaceuticals (NASDAQ: INM) Secures International Patent for Novel Compounds - Defense World
InMed Pharmaceuticals Secures Key Patent for Cannabinoid Analogs - TipRanks
InMed Pharmaceuticals secures international patent - Investing.com India
InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds - Newsfile
InMed Secures Breakthrough 20-Year Patent in Mexico for Novel Cannabinoid Compounds - StockTitan
Nano-Cap InMed Ignites Retail Frenzy As Stock Soars After Alzheimer's Drug Trial Shows Promise - Asianet Newsable
InMed Pharmaceuticals (NASDAQ: INM) Announces Positive Results from INM-901 Alzheimer’s Disease Study - Defense World
InMed Hails Alzheimer's Study, Stocks Shoot Higher - Baystreet.ca
InMed announces ‘positive’ results from in vivo preclinical Alzheimer’s study - TipRanks
InMed’s INM-901 Shows Promising Results in Preclinical Alzheimer’s Study - TipRanks
InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study - Newsfile
InMed's Alzheimer's Drug Shows Breakthrough Results in Reducing Brain Inflammation - StockTitan
SABBY MANAGEMENT, LLC Acquires Shares in InMed Pharmaceuticals I - GuruFocus.com
InMed Pharmaceuticals Inc. Holds 2024 Annual General Meeting – Elects Directors and Appoints Auditor - Defense World
InMed Pharmaceuticals Director Faces Resignation After Shareholder Vote at Annual Meeting - StockTitan
InMed Announces Results of 2024 Annual General Meeting - Newsfile
InMed Pharmaceuticals Inc. announced that it expects to receive CAD 10 million in funding - Marketscreener.com
InMed Enters Into Standby Equity Purchase Agreement - Newsfile
Head-To-Head Review: InMed Pharmaceuticals (NASDAQ:INM) & Rocket Pharmaceuticals (NASDAQ:RCKT) - Defense World
InMed Pharmaceuticals Secures $10M Equity Purchase Agreement in Strategic Financing Move - StockTitan
InMed Pharmaceuticals (TSE:IN) Trading Down 1.6% – Time to Sell? - Defense World
InMed Pharmaceuticals (FRA:MWG) Altman Z-Score : -14.86 (As of Dec. 05, 2024) - GuruFocus.com
InMed Pharmaceuticals (FRA:MWG) Altman Z-Score : -14.90 (As of Dec. 03, 2024) - GuruFocus.com
InMed Pharmaceuticals (FRA:MWG) Inventories, Finished Goods : €0.84 Mil (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (FRA:MWG) Shares Outstanding (EOP) : 0.67 Mil (As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Total Liabilities : $2.07 Mil (As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Debt-to-Equity : 0.13 (As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Dividend Yield % : 0.00% (As of Nov. 26, 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Dividend Payout Ratio : 0.00 (As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) EBITDA : $-6.66 Mil (TTM As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) 3-Year Dividend Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Cash, Cash Equivalents, Marketa - GuruFocus.com
INM (InMed Pharmaceuticals) Growth Rank : 0 (As of Nov. 26, 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Machinery, Furniture, Equipment : $0.04 Mil (As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) 3-Year EPS without NRI Growth R - GuruFocus.com
INM (InMed Pharmaceuticals) Total Inventories : $1.22 Mil (As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Net Income : $-6.82 Mil (TTM As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Inventory Turnover : 0.63 (As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Revenue per Share : $49.03 (TTM As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Forward Dividend Yield % : 0.00% (As of Nov. 26, 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) 9-Day RSI : 44.83 (As of Nov. 26, 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Price-to-Operating-Cash-Flow : (As of Nov. 26, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Ending Cash Position : €5.03 Mil (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (FRA:MWG) EBITDA : €-6.11 Mil (TTM As of Sep. 2024) - GuruFocus.com
0.92%
1.31%
자본화:
|
볼륨(24시간):